Understand the source comparison
ARA-290 vs VIP: Which Is Better? | Real Peptides
Research published in the Journal of Neuroinflammation found that ARA-290 reduced neuropathic pain scores by 42% in patients with sarcoidosis-associated small fiber neuropathy. A result VIP has never replicated in controlled trials. The two peptides operate th
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research published in the Journal of Neuroinflammation found that ARA-290 reduced neuropathic pain scores by 42% in patients with sarcoidosis-associated small fiber neuropathy. A result VIP has never replicated in controlled trials. The two peptides operate through completely separate receptor systems: ARA-290 binds to the tissue-protective receptor (CD131/βcR), while VIP acts on VPAC1 and VPAC2 receptors that regulate immune cell function. This isn't a subtle difference. It determines which peptide matches specific research objectives.
- Our team has supplied both compounds to hundreds of research institutions conducting parallel studies on neuroprotection, immune modulation, and tissue repair. The question we hear most often isn't which peptide is 'better'. It's which mechanism aligns with the specific biological pathway under investigation.
- What's the core difference between ARA-290 and VIP?
- ARA-290 is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO), binding exclusively to CD131/βcR to activate cellular repair pathways without stimulating red blood cell production. VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide that modulates immune response, vasodilation, and neurotransmitter release through VPAC receptor activation. ARA-290 excels in direct tissue protection studies, while VIP demonstrates broader immunomodulatory effects across multiple organ systems.
- The comparison isn't straightforward because these peptides don't compete for the same research applications. ARA-290 was engineered specifically to isolate EPO's tissue-protective properties. Removing hematopoietic effects that made full-length EPO unsuitable for non-anemia conditions. VIP evolved as an endogenous signaling molecule with pleiotropic effects across nervous, immune, and cardiovascular systems. Choosing between them requires mapping your research question to the correct biological mechanism. This article covers receptor binding specificity, tissue distribution patterns, documented efficacy in neuroprotection models, immune modulation differences, clinical trial outcomes, and practical considerations for researchers selecting between these compounds.